WO2010032974A2 - 아데포비어디피복실의 개선된 제조방법 - Google Patents
아데포비어디피복실의 개선된 제조방법 Download PDFInfo
- Publication number
- WO2010032974A2 WO2010032974A2 PCT/KR2009/005305 KR2009005305W WO2010032974A2 WO 2010032974 A2 WO2010032974 A2 WO 2010032974A2 KR 2009005305 W KR2009005305 W KR 2009005305W WO 2010032974 A2 WO2010032974 A2 WO 2010032974A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- adefovir
- adefovir difficile
- compound
- difficile
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Definitions
- the present invention relates to an improved method for preparing adefovir difficile useful as an antiviral agent, wherein adefovir difficile is 9- [2-[[bis ⁇ (pivaloyloxy) -methoxy ⁇ phosphinyl] methoxy] ethyl]
- Adenine is a substance known from U.S. Pat.
- the present invention provides 9- [2-[[bis ⁇ (pivaloyloxy)-of formula 1 using 9- [2- (phosphonomethoxy) ethyl] adenine ("adefovir") of formula 2 as starting material.
- Adefovir difficile is a drug useful as an antiviral therapeutic agent, a nucleotide reverse transcriptase inhibitor, and has a particularly therapeutic effect on hepatitis B and HIV and is marketed under the name Hepsera.
- adefovir difficile Prior art for the preparation of adefovir difficile includes dimethylformamide (DMF) and N, N-dicyclohexyl-4-morpholine-carbox at 22 ° C. using adefovir of Formula 2 in US Pat.
- a method of synthesizing Scheme 1 is disclosed, which synthesizes adefovir difficile acid of Formula 1 in 32% yield by reacting with chloromethylpivalate in the presence of amidine.
- the method has a problem in that the yield is low due to the generation of many by-products during the reaction.
- Adefovir of Chemical Formula 2 was used as a starting material in Korean Patent No. 0700087, and chloromethylpivalate was present in the presence of 1-methyl-2-pyrrolidinone (NMP) and triethylamine (TEA).
- NMP 1-methyl-2-pyrrolidinone
- TAA triethylamine
- the reaction yield was improved to about 55%, but the reaction temperature should be warmed to 60 ° C. or higher, resulting in a large amount of flexible substances, and the reaction with 1-methyl-2-pyrrolidinone used in the reaction. More than about 15% of byproducts of 3 are generated, which leads to difficulty in the purification process.
- an object of the present invention is to provide a novel method for preparing adefovir difficile acid of Chemical Formula 1, which has excellent reaction yield and improved reaction conditions.
- the use has led to the development of an improved process for the preparation of adefovir difficile compounds of formula (1) which achieves this object.
- the present invention provides 9- [2-[[bis ⁇ (pivaloyloxy)-of formula 1 using 9- [2- (phosphonomethoxy) ethyl] adenine (“adefovir”) of formula 2 as starting material.
- adefovir 9- [2-[[bis ⁇ (pivaloyloxy)-of formula 1 using 9- [2- (phosphonomethoxy) ethyl] adenine (“adefovir”) of formula 2 as starting material.
- adefovir 9- [2-[[bis ⁇ (pivaloyloxy)-of formula 1 using 9- [2- (phosphonomethoxy) ethyl] adenine (“adefovir”) of formula 2 as starting material.
- adefovir difficile 9- [2-[[bis ⁇ (pivaloyloxy)-of formula 1 using 9- [2- (phosphonomethoxy) ethyl] adenine
- the preparation method according to the present invention is characterized in that dimethyl sulfoxide is used instead of 1-methyl-3-pyrrolidinone as a reaction solvent, and the adefovir of Formula 2 is subjected to chloromethyl pival under a solvent of dimethyl sulfoxide and triethylamine. Reacting the rate with 30 ° C. to 50 ° C. for 3 to 7 hours to produce adefovir difficile acid of Formula 1.
- adefovir difficile prepared by the production method according to the invention is characterized in that it comprises less than 15% by-product of formula (3).
- the production process according to the present invention comprises less than 15% of the by-product of formula 3 in the final product to provide adefovir difficile with high yield and high quality.
- the production method according to the present invention has a smaller amount of the flexible material generated by the reaction proceeds more quickly even at a lower reaction temperature than the conventional production method (using NMP).
- Example 1 is an HPLC analysis data of the composition carried out by Example 1.
- Example 2 is an HPLC analysis of the composition carried out by Example 2.
- FIG. 3 is an HPLC analysis of the composition carried out in Example 3.
- Adefovir of Formula 2 is added to the mixture of dimethylsulfoxide and triethylamine, followed by dropwise addition of chloromethylpivalate. After stirring for 3 to 7 hours while maintaining the reaction temperature at 30 °C to 50 °C to obtain adefovir difficile acid of formula (1).
- the present invention may further comprise the following purification process to remove impurities of the by-products contained in the prepared adefovir difficile acid of the formula (1).
- the purification process comprises the steps of dissolving the prepared adefovir difficile compound of Formula 1 in water or a mixed solvent containing water; Purifying the adefovir difficile solution through a reversed phase column; And adding a base to the purified adefovir difficile solution and extracting with an organic solvent.
- the purification process adds water or a mixed solvent including water to an impure adefovir difficile-containing organic solvent layer containing by-products prepared through synthesis, and then adds an acid and extracts into an aqueous layer .
- a mixed solvent including water refers to an organic solvent in which at least 20% by weight of water is dissolved.
- suitable organic solvents include alcohols having 1 to 4 carbon atoms, acetone, acetonitrile, tetrahydrofuran, dioxane, and the like. Including, but not limited to.
- adefovir difficile containing by-products in the container solvent may be in the salt or complex state thereof and dissolved in water or a mixed solvent including water.
- adefovir difficile salt or complex herein is meant a compound formed by adding adefovir difficile and an inorganic or organic acid.
- both an organic acid and an inorganic acid may be used, and hydrochloric acid, sulfuric acid, nitric acid, methanesulfonic acid and the like are preferable in consideration of the formation of adefovir difficile salts or complexes.
- the pH of the extracted aqueous solution is 0.1 to 5.0, preferably 1.0 to 3.0.
- the separated aqueous solution is passed through a reversed phase column, and the passed liquid is recovered. Thereafter, if necessary, an aqueous solution (mobile phase) between 0.1 and 5.0, preferably 1.0 to 3.5, may be further recovered by passing through an inverse column.
- the filling material (still phase) of the reversed phase column used herein includes a polymer material which is insoluble in water such as C 1 to C 18 alkyl or HP 2 0, and preferably octadecyl having 18 carbon atoms.
- An organic solvent is added to the recovered aqueous solution, and a base material is added to adjust the pH of the aqueous solution to between 2.5 and 10. Thereafter, the organic solvent is separated.
- Organic solvents used herein include dichloromethane, isopropyl acetate, toluene, ethyl acetate, and the like, and preferably dichloromethane and isopropyl acetate.
- the base material to be used may be both inorganic base and organic base, and considering the formation of the flexible material, the preferred pH of the aqueous solution to which the base material is added is 2.5 to 6.5.
- the recovered organic solvent is then removed to obtain a purified high purity amorphous adefovir difficile solid.
- the method of evaporating the organic solvent includes a reduced pressure concentration method, and when concentrated, the internal temperature is preferably between 30 °C ⁇ 90 °C.
- the adefovir difficile compound represented by Chemical Formula 1 is dissolved in a hydrocarbon having 5 to 12 carbon atoms, such as n-pentane, n-hexane or n-heptane or cyclohexane, in addition to the vacuum concentration method.
- a hydrocarbon having 5 to 12 carbon atoms such as n-pentane, n-hexane or n-heptane or cyclohexane
- the purity of the adefovir difficile purified according to the invention is at least 95%, preferably at least 99%.
- the obtained compound was analyzed via HPLC.
- the column used for HPLC analysis was Alltech Mixed Mode ExchangeTM C8 (7 u, 100 kPa), the flow rate was 1.2 ml / min, the detector was an ultraviolet absorption photometer (wavelength: 260 nm), and the column temperature was analyzed at room temperature.
- Mobile phase A was used by mixing phosphate buffer (pH 6.0): acetonitrile in a 70:30 ratio
- mobile phase B was used by mixing phosphate buffer (pH 6.0): acetonitrile in a 50:50 ratio.
- the diluent was used by mixing phosphate buffer (pH 3.0): acetonitrile in a 20:30 ratio.
- the flow rate changes in the column analysis of mobile phase A and mobile phase B are as follows.
- FIG. 1 Analytical data of the compound of Example 1 obtained by HPLC under the above conditions is shown in FIG. 1 (RetTime (min): 10.142, Width (min): 0.27, Area (mAU * s of adefovir difficile compound of Chemical Formula 1)). ): 1.4556le4, Height (mAU): 810.53, Area (%): 61.55, RetTime (minutes) of the by-product of Formula 3: 9.236, Width: 0.23, Area (mAU * s): 2927.66, Height (mAU) ): 184.96, Area (%) 12.38).
- HPLC analysis data of the composite obtained in Example 2 is shown in Figure 2 (RetTime (minutes): 9.944, Width (minutes): 0.23, Area (mAU * s): 8248.92, Height (Adefovir difficile compound of Formula 1). mAU): 549.31, Area (%): 75.68, RetTime (minutes) of the by-product of formula 3: 9.228, Width (minutes): 0.22, Area (mAU * s): 1208.14, Height (mAU): 85.30, Area (% ) 11.08).
- HPLC analysis data of the composite obtained in Example 3 is shown in Figure 3 (RetTime (minutes): 11.518, Width (minutes): 0.22, Area (mAU * s): 9995.02, Height (Adefovir difficile compound of Formula 1) mAU): 682.72, Area (%): 73.83, RetTime (minutes) of the by-product of formula 3: 10.466, Width (minutes): 0.24, Area (mAU * s): 1735.54, Height (mAU): 122.53, Area (% 12.82).
- the obtained compound was analyzed via HPLC.
- the HPLC analysis conditions are the same as in Example 1 above.
- HPLC analysis data of the composite obtained in Example 4 is shown in Figure 4 (RetTime (minutes): 10.947, Width (minutes): 0.20, Area (mAU * s): 2.40482e4, Height of the adefovir difficile compound of Formula 1 (mAU): 1845.69, Area (%): 82.04, RetTime (minutes) of the by-product of formula 3: 10.106, Width (minutes): 0.18, Area (mAU * s): 2710.89, Height (mAU): 232.66, Area ( %) 9.25).
- Example 2 3000 ml of purified water was added to the organic layer obtained in Example 1. Thereafter, the pH of the purified water was adjusted to 1.8 using 1N aqueous hydrochloric acid, and then stirred at 20 to 25 ° C. for 10 minutes. After the stirring was stopped, the aqueous layer was separated. The separated aqueous layer was passed through a C18 reversed phase column (size: 40 * 15cm, packing material: KP-C18-HSTM 35-70um, 9 ⁇ C18-bonded silica, manufactured by Biotage).
- the aqueous solution which passed the C18 reverse phase column was collect
- the recovered aqueous solution was recovered by passing it through a C18 reversed phase column again, and 500 ml of dichloromethane was added to the recovered aqueous solution.
- the pH of the recovered aqueous solution was adjusted to between 5.5 and 5.6 by dropwise addition of 5% aqueous sodium bicarbonate solution while stirring the reaction.
- the aqueous solution which passed the C18 reverse phase column was collect
- the recovered aqueous solution was recovered by passing it back through a C18 reversed phase column, and 500 ml of dichloromethane was added to the recovered aqueous solution. 5% sodium bicarbonate aqueous solution was added dropwise while stirring the reaction to adjust the pH of the recovered aqueous solution between 3.2 and 3.3.
- the aqueous solution which passed the C18 reverse phase column was collect
- the recovered aqueous solution was recovered by passing it back through a C18 reversed phase column, and 500 ml of dichloromethane was added to the recovered aqueous solution. While stirring the reaction, 5% aqueous sodium bicarbonate solution was added dropwise to adjust the pH of the recovered aqueous solution to between 3.1 and 3.2.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
시간(분) | 이동상 A(%) | 이동상 B(%) |
0 내지 19 | 100→0 | 0→100 |
19 내지 36 | 0 | 100 |
36 내지 46 | 0→100 | 100→0 |
Claims (7)
- 제1항에 있어서, 반응 온도가 30℃ 내지 50℃에서 수행됨을 특징으로 하는, 제조 방법.
- 제1항 내지 제3항 중 어느 하나의 항에 있어서, 반응 시간이 3 내지 7시간임을 특징으로 하는, 제조 방법.
- 제1항 내지 제3항 중 어느 하나의 항에 있어서, 제조된 화학식 1의 아데포비어 디피복실의 정제 공정을 추가로 포함함을 특징으로 하는, 제조 방법.
- 제5항에 있어서, 정제 공정이, 제조된 화학식 1의 아데포비어 디피복실을 물 또는 물을 포함한 혼합용매에 용해시키는 단계; 아데포비어 디피복실 용액을 역상컬럼으로 통해 정제하는 단계; 및 정제된 아데포비어 디피복실 용액에 염기를 첨가하고 유기용매로 추출하는 단계를 포함함을 특징으로 하는, 제조 방법.
- 제6항에 있어서, 물을 포함한 혼합용매가, 물이, 탄소수 1 내지 4의 알코올, 아세톤, 아세토니트릴, 테트라하이드로푸란 및 디옥산으로 이루어진 그룹 중 하나 이상 선택된 용매에 20중량% 이상으로 용해되어 있는 용매인, 제조 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/119,538 US8637669B2 (en) | 2008-09-18 | 2009-09-17 | Production method for adefovir dipivoxil |
EP09814790A EP2330107A4 (en) | 2008-09-18 | 2009-09-17 | PROCESS FOR THE IMPROVED PRODUCTION OF ADEFOVIR DIPIVOXIL |
CN200980136627.7A CN102159576B (zh) | 2008-09-18 | 2009-09-17 | 肝适能制备的改良方法 |
JP2011527747A JP2012502984A (ja) | 2008-09-18 | 2009-09-17 | アデホビルジピボキシルの改善された製造方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0091390 | 2008-09-18 | ||
KR20080091390 | 2008-09-18 | ||
KR1020090001394A KR20100032803A (ko) | 2008-09-18 | 2009-01-08 | 아데포비어디피복실의 개선된 제조방법 |
KR10-2009-0001394 | 2009-01-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010032974A2 true WO2010032974A2 (ko) | 2010-03-25 |
WO2010032974A3 WO2010032974A3 (ko) | 2010-06-24 |
Family
ID=42181935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/005305 WO2010032974A2 (ko) | 2008-09-18 | 2009-09-17 | 아데포비어디피복실의 개선된 제조방법 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8637669B2 (ko) |
EP (1) | EP2330107A4 (ko) |
JP (1) | JP2012502984A (ko) |
KR (2) | KR20100032803A (ko) |
CN (1) | CN102159576B (ko) |
TW (1) | TWI445711B (ko) |
WO (1) | WO2010032974A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101891767A (zh) * | 2010-07-21 | 2010-11-24 | 浙江贝得药业有限公司 | 一种阿德福韦酯的制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100031045A (ko) * | 2008-09-11 | 2010-03-19 | 씨제이제일제당 (주) | 아데포비어 디피복실의 정제방법 |
BR102014031844A2 (pt) * | 2013-12-20 | 2015-10-06 | Dow Agrosciences Llc | ras oposto (rop) e moléculas de ácido nucleico relacionadas que conferem resistência a pragas de coleópteros e hemípteros |
CN106167503B (zh) * | 2016-07-07 | 2018-06-22 | 福建广生堂药业股份有限公司 | 一种阿德福韦酯羟甲基杂质的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663159A (en) | 1990-09-14 | 1997-09-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
KR100700087B1 (ko) | 1997-07-25 | 2007-03-28 | 길리애드 사이언시즈, 인코포레이티드 | 뉴클레오티드 동족체의 제조 방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA986614B (en) * | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
ES2322245T3 (es) * | 2001-12-21 | 2009-06-18 | Eisai Corporation Of North America | Procedimiento para preparar derivados del fosfonooximetil de alcohol y fenol solubles en agua. |
EP1907391A1 (en) * | 2005-07-26 | 2008-04-09 | Hetero Drugs Limited | Novel process for acyclic phosphonate nucleotide analogs |
CN1935818B (zh) * | 2006-09-22 | 2011-11-09 | 闫敬武 | 阿德福韦酯新晶态、晶态组合物、制备方法及应用 |
CN101357930B (zh) * | 2008-09-09 | 2011-06-29 | 珠海联邦制药股份有限公司 | 一种阿德福韦酯的制备方法 |
KR20100031045A (ko) * | 2008-09-11 | 2010-03-19 | 씨제이제일제당 (주) | 아데포비어 디피복실의 정제방법 |
-
2009
- 2009-01-08 KR KR1020090001394A patent/KR20100032803A/ko active Search and Examination
- 2009-09-17 EP EP09814790A patent/EP2330107A4/en not_active Withdrawn
- 2009-09-17 US US13/119,538 patent/US8637669B2/en active Active
- 2009-09-17 CN CN200980136627.7A patent/CN102159576B/zh not_active Expired - Fee Related
- 2009-09-17 JP JP2011527747A patent/JP2012502984A/ja active Pending
- 2009-09-17 KR KR1020090088155A patent/KR100976762B1/ko active IP Right Grant
- 2009-09-17 WO PCT/KR2009/005305 patent/WO2010032974A2/ko active Application Filing
- 2009-09-18 TW TW098131576A patent/TWI445711B/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663159A (en) | 1990-09-14 | 1997-09-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
KR100700087B1 (ko) | 1997-07-25 | 2007-03-28 | 길리애드 사이언시즈, 인코포레이티드 | 뉴클레오티드 동족체의 제조 방법 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2330107A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101891767A (zh) * | 2010-07-21 | 2010-11-24 | 浙江贝得药业有限公司 | 一种阿德福韦酯的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20100032839A (ko) | 2010-03-26 |
WO2010032974A3 (ko) | 2010-06-24 |
EP2330107A4 (en) | 2011-10-19 |
CN102159576B (zh) | 2014-08-06 |
EP2330107A2 (en) | 2011-06-08 |
KR100976762B1 (ko) | 2010-08-19 |
US8637669B2 (en) | 2014-01-28 |
TW201016714A (en) | 2010-05-01 |
CN102159576A (zh) | 2011-08-17 |
US20110207930A1 (en) | 2011-08-25 |
JP2012502984A (ja) | 2012-02-02 |
TWI445711B (zh) | 2014-07-21 |
KR20100032803A (ko) | 2010-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100970434B1 (ko) | 아데포비어 디피복실의 정제방법 | |
CA2126601A1 (en) | Phosphonate-nucleotide ester derivatives | |
WO2010104336A2 (ko) | 아연 분말을 이용한 메로페넴의 개선된 제조방법 | |
WO2010032974A2 (ko) | 아데포비어디피복실의 개선된 제조방법 | |
WO2019231166A1 (ko) | 슈가마덱스 나트륨염의 제조방법 | |
WO2022164150A1 (ko) | 나파모스타트 메실산염 및 그의 중간체의 제조방법 | |
EP3365332A1 (en) | Preparation method of intermediate for oxazolidinone derivative | |
KR20230026411A (ko) | 방향족 에터 화합물의 제조 방법 | |
CN110372750B (zh) | 一种富马酸替诺福韦酯杂质的合成方法 | |
WO2009128631A2 (ko) | 라세믹 또는 광학적으로 활성이 있는 α-글리세로포스포릴 콜린 및 그의 유도체의 제조방법 | |
WO2022092774A1 (ko) | 포말리도마이드로부터 3,6'-디티오포말리도마이드를 선택적으로 합성하는 방법 | |
WO2018084625A1 (en) | Method for preparation of (s)-n1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride | |
WO2012157977A9 (en) | Manufacturing method of heterocyclic compound | |
WO2010110506A1 (en) | Dh-type crystalline form of adefovir dipivoxil, preparing method thereof, and pharmaceutical composition for antiviral agent comprising the same | |
CN112920114B (zh) | 一种硫酸羟氯喹的合成方法 | |
WO2021071130A1 (ko) | 5'-구아닐산이나트륨 7수화물 결정의 제조 방법 | |
CN106831853A (zh) | 7‑乙基‑10‑o‑叔丁基二苯基硅基喜树碱‑20‑o‑甘氨酸盐酸盐的制备工艺 | |
WO2022055267A1 (ko) | 알킬-d-알라니네이트의 제조방법 | |
EP0548834B1 (en) | Stable hexahydrate of etoposide 4'-phosphate disodium salt | |
WO2020085616A1 (ko) | 아픽사반의 제조방법 | |
WO2010005175A2 (ko) | 신규한 결정형 실라스타틴 암모늄염 및 그 제조방법 | |
US9505792B2 (en) | Forms of cidofovir | |
CN114195784A (zh) | 帕博西尼有关物质及其制备方法和应用 | |
WO2020213911A1 (ko) | 날데메딘의 제조방법 | |
CN111484540A (zh) | 含双核苷酸结构的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980136627.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09814790 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011527747 Country of ref document: JP Ref document number: 2009814790 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13119538 Country of ref document: US |